Clinical Trials
56 trialsNCT04784715 2026-05-22
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
AstraZeneca
Phase 3 Active not recruiting
NCT04802759 2026-05-11
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT06625775 2026-04-13
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1 Recruiting
NCT07007559 2026-04-13
ASPEN-09-03
ALX Oncology Inc.
Phase 2 Recruiting
NCT05143970 2026-03-20
CHANCES
Institut Paoli-Calmettes
Phase 1 Recruiting
NCT01613482 2026-03-16
TSARINE
Centre Oscar Lambret
Phase 3 Terminated
NCT05081609 2026-02-24
IL Believe
Ascendis Pharma A/S
Phase 1/2 Active not recruiting
NCT07193394 2026-02-23
H3RAKLES
Institut Curie
Phase 2 Recruiting
NCT00781612 2025-12-24
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Genentech, Inc.
Phase 2 Active not recruiting
NCT01771458 2025-11-24
SHIVA
Institut Curie
Phase 2 Completed
NCT03013218 2025-08-01
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
ALX Oncology Inc.
Phase 1 Completed
NCT00393783 2025-06-05
Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT00317720 2025-04-30
Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02492711 2025-03-17
SOPHIA
MacroGenics
Phase 3 Completed
NCT04551521 2025-01-08
CRAFT: The NCT-PMO-1602 Phase II Trial
German Cancer Research Center
Phase 2 Completed
NCT04307329 2024-10-22
MIMOSA
The Netherlands Cancer Institute
Phase 2 Completed
NCT04120246 2024-07-10
Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer
Veana Therapeutics
Phase 1 Suspended
NCT01953926 2024-03-12
SUMMIT
Puma Biotechnology, Inc.
Phase 2 Terminated
NCT03783936 2023-12-19
Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas
Hoosier Cancer Research Network
Phase 2 Completed
NCT01300962 2023-12-04
Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT06121700 2023-11-08
Miracle-G
Fudan University
Phase 2 Recruiting
NCT01969643 2023-03-07
A Safety Study of SGN-LIV1A in Breast Cancer Patients
Seagen Inc.
Phase 1 Completed
NCT00807859 2022-11-08
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Amgen
Phase 1 Completed
NCT00810017 2022-05-19
Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer
Medstar Health Research Institute
Phase 2 Terminated
NCT00297596 2021-10-28
Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT04464967 2021-05-12
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
Phase 1/2 Withdrawn
NCT01835236 2021-03-30
Trastuzumab & Pertuzumab Followed by T-DM1 in MBC
Swiss Cancer Institute
Phase 2 Completed
NCT02139358 2021-02-04
Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT01285466 2020-12-09
A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab
Novartis
Phase 1 Completed
NCT01271920 2020-12-08
Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab
Novartis
Phase 1/2 Completed
NCT01387373 2020-10-05
Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Breast Cancer
Herlev Hospital
Phase 2 Completed
NCT00367471 2020-09-09
Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.
Novartis
Phase 1 Completed
NCT01396707 2020-01-07
Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOX
Asan Medical Center
Phase 2 Completed
NCT00140140 2019-11-26
A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer
Celgene
Phase 1/2 Terminated
NCT03811418 2019-11-26
ATTILA
iOMEDICO AG
Phase 3 Withdrawn
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT00876395 2018-12-19
BOLERO-1
Novartis
Phase 3 Completed
NCT00428922 2018-08-09
Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT03588533 2018-07-17
HERZUMA-GC
Dong-A University Hospital
Phase 2 Unknown
NCT00201760 2017-12-27
Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT01512199 2017-10-18
Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)
Daiichi Sankyo
Phase 1/2 Terminated
NCT01774851 2017-06-22
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
Merrimack Pharmaceuticals
Phase 2 Terminated
NCT01364493 2017-05-09
A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer
Peking University
Phase 2 Completed
NCT01304797 2017-01-06
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
Merrimack Pharmaceuticals
Phase 1 Unknown
NCT02238509 2016-06-15
Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies
Consorzio Oncotech
Phase 2 Unknown
NCT01048099 2016-01-29
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase NA Completed
NCT01985893 2016-01-14
THOR
Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V.
Phase 2 Withdrawn
NCT00426556 2015-12-28
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
Novartis
Phase 1 Completed
NCT00377780 2015-09-23
MYOHERTAX
Catharina Ziekenhuis Eindhoven
Phase 2 Terminated
NCT01242449 2015-05-21
OVINTRA
Vejle Hospital
Phase 2 Completed